Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis

Scandinavian Journal of Immunology

Volumn 64, Issue 6, 2006, Pages 609-622

  Tham, E ^a,c   Gielen, A W ^a   Khademi, M ^a   Martin, C ^b   Piehl, F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL LEVEL; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL MODEL; FEMALE; GENE CONTROL; GLIA; GUINEA PIG; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MONOCYTE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; SPINAL CORD;

ADOLESCENT; ADULT; ALTERNATIVE SPLICING; ANIMALS; CEREBROSPINAL FLUID; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROGLIA; NEURONS; RATS; RATS, INBRED LEW; RNA, MESSENGER; SPINAL CORD; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33750688816     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01851.x     Document Type: Article

References (81)

1. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
2. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
3. Gerber HP, Hillan KJ, Ryan AM et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-59.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
5. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005;65:550-63.
6. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995;77:638-43.
7. Clauss M, Gerlach M, Gerlach H et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-45.
8. Heil M, Clauss M, Suzuki K et al. Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol 2000;79:850-7.
9. Reinders ME, Sho M, Izawa A et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003;112:1655-65.
10. Croll SD, Ransohoff RM, Cai N et al. VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp Neurol 2004;187:388-402.
11. Proescholdt MA, Heiss JD, Walbridge S et al. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol 1999;58:613-27.
12. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue - beyond blood vessels. Exp Neurol 2004;187:246-53.
13. Benton RL, Whittemore SR. VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem Res 2003;28:1693-703.
14. Widenfalk J, Lipson A, Jubran M et al. Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience 2003;120:951-60.
15. Zhang ZG, Zhang L, Tsang W et al. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 2002;22:379-92.
16. Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.
17. Oosthuyse B, Moons L, Storkebaum E et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
18. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114:853-65.
19. Ruhrberg C. Growing and shaping the vascular tree: multiple roles for VEGF. Bioessays 2003;25:1052-60.
20. Jin KL, Mao XO, Nagayama T, Goldsmith PC, Greenberg DA. Induction of vascular endothelial growth factor and hypoxia-inducible factor-1 alpha by global ischemia in rat brain. Neuroscience 2000;99:577-85.
21. Renner W, Pilger E. Simultaneous in vivo quantitation of vascular endothelial growth factor mRNA splice variants. J Vasc Res 1999;36:133-8.
22. Ishida S, Usui T, Yamashiro K et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-9.
23. Usui T, Ishida S, Yamashiro K et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004;45:368-74.
24. Grimmond S, Lagercrantz J, Drinkwater C et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 1996;6:124-31.
25. Olofsson B, Pajusola K, Kaipainen A et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 1996;93:2576-81.
26. Mould AW, Greco SA, Cahill MM et al. Transgenic overexpression of vascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ Res 2005;97:e60-70.
27. Aase K, von Euler G, Li X et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 2001;104:358-64.
28. Bellomo D, Headrick JP, Silins GU et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000;86:E29-35.
29. Sun Y, Jin K, Childs JT et al. Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. J Cereb Blood Flow Metab 2004;24:1146-52.
30. Mould AW, Tonks ID, Cahill MM et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum 2003;48:2660-9.
31. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002;82:673-700.
32. Autiero M, Waltenberger J, Communi D et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43.
33. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med 2003;13:169-75.
34. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003;206:187-91.
35. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003;13:554-73.
36. Kirk SL, Karlik SJ. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 2003;21:353-63.
37. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 2002;61:914-25.
38. Su JJ, Osoegawa M, Matsuoka T et al. Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 2006;243:21-30.
39. Ludwin S. Vascular proliferation and angiogenesis in MS: clinical and pathogenic implications. J Neuropath Exp Neurol 2001;60:505.
40. Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 1993;44:959-66.
41. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation crosstalk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004;172:4618-23.
42. Swanborg RH. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol Rev 2001;184:129-35.
43. Weissert R, Svenningsson A, Lobell A et al. Molecular and genetic requirements for preferential recruitment of TCRBV8S2+ T cells in Lewis rat experimental autoimmune encephalomyelitis. J Immunol 1998;160:681-90.
44. Muhallab S, Lundberg C, Gielen AW et al. Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand J Immunol 2002;55:264-73.
45. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
46. Khademi M, Illes Z, Gielen AW et al. T Cell Ig- and mucin-domain- containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004;172:7169-76.
47. Jin P, Zhao Y, Ngalame Y et al. Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 2004;5:55.
48. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
49. Tham E, Wang J, Piehl F, Weber G. Upregulation of VEGF-A without angiogenesis in a mouse model of dilated cardiomyopathy caused by mitochondrial dysfunction. J Histochem Cytochem 2002;50:935-44.
50. Lidman O, Olsson T, Piehl F. Expression of nonclassical MHC class I (RT1-U) in certain neuronal populations of the central nervous system. Eur J Neurosci 1999;11:4468-72.
51. Gielen AW, Lobell A, Lidman O et al. Expression of T cell immunoglobulin-and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems. J Neuroimmunol 2005;164:93-104.
52. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994;36 (Suppl.):S47-53.
53. Fujita M, Mason RJ, Cool C et al. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol 2002;93:2162-70.
54. Kawano Y, Matsui N, Kamihigashi S, Narahara H, Miyakawa I. Effects of interferon-gamma on secretion of vascular endothelial growth factor by endometrial stromal cells. Am J Reprod Immunol 2000;43:47-52.
55. Trompezinski S, Denis A, Vinche A, Schmitt D, Viac J. IL-4 and interferon-gamma differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts. Exp Dermatol 2002;11:224-31.
56. Yano K, Liaw PC, Mullington JM et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006;203:1447-58.
57. Brockington A, Wharton SB, Fernando M et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006;65:26-36.
58. Islamov RR, Chintalgattu V, Pak ES, Katwa LC, Murashov AK. Induction of VEGF and its Flt-1 receptor after sciatic nerve crush injury. Neuroreport 2004;15:2117-21.
59. van Bruggen N, Thibodeaux H, Palmer JT et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 1999;104:1613-20.
60. Manoonkitiwongsa PS, Schultz RL, Whitter EF, Lyden PD. Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains. Vascul Pharmacol 2006;44:316-25.
61. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43.
62. Carmeliet P, Ng YS, Nuyens D et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999;5:495-502.
63. Ruhrberg C, Gerhardt H, Golding M et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002;16:2684-98.
64. Stalmans I, Ng YS, Rohan R et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002;109:327-36.
65. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-54.
66. Krum JM, Khaibullina A. Inhibition of endogenous VEGF impedes revascularization and astroglial proliferation: roles for VEGF in brain repair. Exp Neurol 2003;181:241-57.
67. Hayashi T, Abe K, Itoyama Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab 1998;18:887-95.
68. Storkebaum E, Lambrechts D, Dewerchin M et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92.
69. Devos D, Moreau C, Lassalle P et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004;62:2127-9.
70. Del Bo R, Scarlato M, Ghezzi S et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 2005;57:373-80.
71. Meyer R, Weissert R, Diem R et al. Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci 2001;21:6214-20.
72. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62-6.
73. De Stefano N, Narayanan S, Francis GS et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70.
74. Godde R, Rohde K, Becker C et al. Association of the HLA region with multiple sclerosis as confirmed by a genome screen using <10,000 SNPs on DNA chips. J Mol Med 2005;83:486-94.
75. Lincoln MR, Montpetit A, Cader MZ et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37:1108-12.
76. Lagercrantz J, Farnebo F, Larsson C et al. A comparative study of the expression patterns for VEGF, VEGF-B/VRF and VEGF-C in the developing and adult mouse. Biochim Biophys Acta 1998;1398:157-63.
77. Carmeliet P, Moons L, Luttun A et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
78. Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 1996;27:1865-72; discussion 72-3.
79. Bogen S, Pak J, Garifallou M, Deng X, Muller WA. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med 1994;179:1059-64.
80. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178:449-60.
81. Graesser D, Solowiej A, Bruckner M et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 2002;109:383-92.